By PPN News Staff
The FDA has approved upadacitinib (Rinvoq, AbbVie), a once-daily oral Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX-IR).
The FDA approval of upadacitinib is supported by data from the SELECT program, one of the largest registrational phase 3 programs in RA, with approximately 4,400 patients evaluated across all treatment arms in five